Swiss National Bank Has $3.92 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,400 shares of the specialty pharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. Swiss National Bank’s holdings in Supernus Pharmaceuticals were worth $3,920,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Smartleaf Asset Management LLC increased its holdings in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 870 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at about $72,000. Venturi Wealth Management LLC acquired a new position in Supernus Pharmaceuticals in the fourth quarter worth about $92,000. KBC Group NV lifted its stake in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 929 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $211,000.

Supernus Pharmaceuticals Trading Up 1.1 %

Shares of Supernus Pharmaceuticals stock opened at $33.05 on Wednesday. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 30.89 and a beta of 0.83. The firm’s 50-day moving average price is $35.49 and its two-hundred day moving average price is $35.05. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of recent research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last three months. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.